LAGARRIGUE acquired by ARDIAN & IXO PRIVATE EQUITY
Context
Ardian entered into exclusive negotiations to acquire a majority stake in Lagarrigue from Azulis Capital. The transaction allowed the management team to reinforce their equity stake. Historical minority investor iXO Private Equity reinvested, while Azulis Capital, Galia Gestion, and BNP Paribas Developpement fully exited. This deal marked the transition from a regional SME to a national leader with international ambitions. The roadmap focused on external growth and digital transformation.
It is worth noting that the fund Azulis Capital / Bnp Paribas Developpement / Galia took control of Lagarrigue through an LBO in 2011.
LAGARRIGUE, which reported an EBITDA margin of [members only] in 2016, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Based in Toulouse, Lagarrigue is a leading French provider of external orthopaedic devices (prosthetics and orthotics). The group specializes in custom-made solutions (95% of activity) for patients with disabilities. Under previous ownership, it tripled its size, expanding into Switzerland, Belgium, and Spain, and digitized its operations through software subsidiaries (Rodin 4D, Vorum).
Ent. Value
€50–100M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with LAGARRIGUE
Other operations with LAGARRIGUE
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2021 | NAXICAP PARTNERS | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 05/2011 | AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA | LAGARRIGUE | FRANCE | Implants & Prosthetics |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2017 | ARDIAN | UNITHER | FRANCE | CDMO |
| 02/2017 | ECOLAB | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 09/2016 | ARCHIMED | POLYPLUS | FRANCE | R&D Biotech |
| 06/2016 | PAI PARTNERS | ATOS MEDICAL | SWEDEN | Medical Consumables |
| 06/2016 | PAI PARTNERS | ETHYPHARM | FRANCE | Pharma & Biotech |
| 06/2016 | BRIDGEPOINT / RAISE / FLEXSTONE PARTNERS | ACTEON | FRANCE | Medical Devices |
| 05/2016 | IK PARTNERS | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 03/2016 | CVC | DOC GENERICI | ITALY | Generics / Labs |
| 03/2016 | PSP INVESTMENTS | ANTELLIQ | FRANCE | Animal Health |
| 02/2016 | ASTORG / GOLDMAN SACHS | HRA PHARMA | FRANCE | Generics / Labs |
Other operations with ARDIAN / IXO PRIVATE EQUITY
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | ARDIAN | Munich Electrification | GERMANY | Batteries & EV Tech |
| 07/2026 | ARDIAN | Pflegia | GERMANY | Recruitment / Headhunting |
| 07/2026 | ARDIAN / EURAZEO / UBS | HR PATH | FRANCE | ERP, HR & Finance |
| 01/2026 | ARDIAN | IVB Wellness Lab | SPAIN | Nutrition & Dietary Supplements |
| 12/2025 | ARDIAN | Fermax | SPAIN | Safety & Security |
| 07/2025 | ARDIAN | Dovida | SWITZERLAND | Outpatient Care |
| 05/2025 | ARDIAN | MasterGrid | FRANCE | Electrical |
| 03/2025 | ARDIAN | AKUO | FRANCE | Renewables |
| 03/2025 | ARDIAN | DIOT-SIACI | FRANCE | Brokerage |
| 01/2025 | ARDIAN / EURAZEO / ASTORG | SYCLEF | FRANCE | HVAC (Heating/AC) |
REFERENCES
Revenue range: €50–100M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LAGARRIGUE by ARDIAN / IXO PRIVATE EQUITY are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: lagarrigue
Acquirer: ardian / ixo private equity